Fox Business - The Power to Prosper
Search Site

Novartis

Stocks to fall 25%?

WSJ Sunday Personal Finance Columnist Jonathan Clements on the benefits of a potential pullback in the markets and strategies for re-allocating your portfolio.

Read More

  1. Developing technology for mobile devices

    InterDigital CEO William Merritt talks business in the technology industry.

  2. Novartis , Google join forces to create ‘smart’ contact lenses

    FBN’s David Asman on Novartis ’ partnership with Google, Facebook’s plans to track users’ TV habits and Morgan Stanley’s report on the potential Apple iWatch.

  3. Spending on pets surges

    Aratana Therapeutics CEO Steven St. Peter on what’s driving growth in the animal-health business.

  4. Eli Lilly CEO talks M&A

    Eli Lilly CEO John Lechleiter argues the company doesn’t need to make bid deals to grow.

  5. Ford CEO: I believe technology makes people better drivers

    Ford CEO Alan Mulally on technology in cars, the leadership transition at the automaker and balancing his work and family life.

  6. European PMI data mixed

    Markets.com chief economist Bill Hubard with the latest on the European markets.

  7. More M&A deals on the way?

    John Eade of the Argus Research Company and Mizuho chief investments strategist Carmine Grigoli discuss the M&A market and where the growth is.

  8. Who will be the number one pick in the NFL draft?

    The Vinnie from Queens panel weighs in on the NFL draft and the NBA playoffs.

  9. AstraZeneca Plans Spin-Offs

    AstraZeneca announced faster-than-expected progress of its experimental cancer drugs and plans to spin off billions of dollars of non-core assets as it staked a clai...

  10. Zimmer to Buy Biomet In $13.35B Deal

    Medical device maker Zimmer Holdings Inc said it would buy orthopedic products company Biomet Inc in a deal valued at about $13.35 billion to broaden its portfolio o...

  11. What the GSK, Novartis Deal Means for Biotech

    The loud welcome given by investors to this week's deal for Novartis and GlaxoSmithKline to trade more than $20 billion of assets could trigger more pacts in the pha...

  12. What to expect from pharma

    Robert W. Baird & Co. senior analyst Brian Skorney on what investors can expect from pharma in the second quarter.

  1. How Novartis is revolutionizing the pharma landscape

    Claman on Call: FBN’s Liz Claman with an after-hours web exclusive on the markets, the midterm elections, Novartis ’ on the brink of treatments for cancer and heart failure and the earnings to watch for tomorrow.

  2. New Hampshire, North Carolina the bellwethers for GOP?

    Former Kansas Governor Mark Parkinson and Former Maryland Governor Robert Ehrlich say the key races for Republicans are New Hampshire and North Carolina.

  3. Novartis CEO: Working on a cure for cancer

    Novartis CEO Joseph Jimenez says the company is working on finding a cure for cancer and bringing a revolutionary heart drug to market by 2015.

  4. Cost of cancer treatments

    Radiation oncologist Dr. Elizabeth Chabner Thompson on the high price tags in the fight against cancer.

  5. Get help in the kitchen from Boris the Robot

    The Real Housewives of New York City's Heather Thomson and The Wall Street Journal’s Veronica Dagher on the new robot that could help you with the dishes and a Dutch teen's unique drone.

  6. Novartis study finds heart failure drug cut cardiovascular deaths

    FBN’s Lauren Simonetti on Compuware and Novartis ’ new heart failure drug.

  7. Lilly CEO sees margins hitting pre-patent cliff levels by ‘19

    Eli Lilly CEO John Lechleiter discusses 2Q earnings and the impact of recent patent expirations.

‹ Prev12345Next ›
Freebase CC-BY
Source: Novartis on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL